Kornimate/medical-research-clean huggingface dataset:
mindfulness in medical training

Conditions: Mindfulness, Burnout, Anxiety, Sleep

Summary: headspace, a smartphone application that provides guided meditation, mindfulness and sleep exercises, will be used as the intervention in improving sleep, anxiety, depression and burnout in all participating individuals selected from the university of arizona college of medicine-tucson residents and fellows.

the intervention of of daily meditation with the headspace application will be used to determine if this is a possible effective intervention for decreasing the feeling of burnout. it is being proposed that it could improve the subjects' well-being both in the short-term and long term. the primary outcomes will be burnout, anxiety, depression and sleep. this study will use the maslach burnout inventory to assess baseline burnout, as well as at 30 and 90 days post-intervention period. sleep and anxiety and depression will be assessed using the epworth sleepiness scale and hospital anxiety and depression scale (hads) scores at the same intervals.

Eligibility criteria:
inclusion criteria: * university of arizona resident or fellow exclusion criteria: * none
empagliflozin for no-reflow phenomenon in pci for stemi

Conditions: STEMI; No-Reflow Phenomenon

Summary: myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. a significant contributor to this issue is reperfusion injury, which enlarges the infarction, deteriorates ventricular function, leads to poorer outcomes, and currently has no specific treatment. originally developed as an antidiabetic, empagliflozin has shown significant benefits in other organs and systems. recent years have seen the demonstration of its cellular and vascular effects in animal models, potentially contributing to the reduction of reperfusion damage. however, no human studies have yet confirmed these effects. consequently, this randomized, parallel-arm clinical trial was designed to evaluate the effect of empagliflozin treatment, administered from the pre-intervention period through to 3 days post-intervention, on the incidence of the no-reflow phenomenon in patients with st-segment elevation myocardial infarction (stemi) undergoing coronary angioplasty compared to a placebo. before entering the hemodynamics room, participants in the intervention group will receive a loading dose of 25 mg of empagliflozin or a standar treatment. in-hospital treatment will continue with 10 mg empagliflozin daily for 3 days for the intervention group. patients will be monitored weekly during the first month and bi-weekly during the second and third months. the primary outcome will be the incidence of the no-reflow phenomenon, measured through the thrombolysis in myocardial infarction (timi) flow scale in the coronary angiography performed to treat the infarction. secondary outcomes will include the reduction of st segment on the electrocardiogram, troponin levels, differences in the longitudinal strain by echocardiogram, and infarct size by magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * acute myocardial infarction with st-segment elevation * presentation to the institute within 12 hours of symptom onset * coronary angioplasty chosen as the reperfusion treatment for the subject * known diagnosis of diabetes or admission glucose \>180 mg/dl. * informed consent signed exclusion criteria: * hemodynamically unstable subjects * subjects undergoing thrombolysis treatment in the current event * history of coronary revascularization surgery * known allergy or hypersensitivity to sodium-glucose co-transporter-2 (sglt2) inhibitors * history of recurrent urinary tract infections * known chronic kidney disease and estimated glomerular filtration rate (egfr) \< 20 * ongoing treatment with any sglt2 inhibitor * participation in another clinical trial or having participated in the week prior to recruitment * for women of childbearing age: current or planned pregnancy or lactation.
rotator cuff integrity and clinical outcomes 5 years after repair.

Conditions: Rotator Cuff Tears; Rotator Cuff Injuries; Rotator Cuff Tear or Rupture, Not Specified as Traumatic

Summary: the study gives an overview of surgically treated rotator cuff injury patients in tartu university hospital sports traumatology centre during 2013-2019 and evaluates the integrity of rotator cuff at minimum 5 years after atraumatic rotator cuff tendon repair. first stage of the study describes the study population, etiology of the injury (traumatic/atraumatic) and aims to answer the question whether the arthroscopic findings are in line with the preoperative imaging studies or not. second stage of the study focuses on atraumatic tendon tears assessing structural integrity of the tendons 5 years after repair using ultrasound imaging. the main question is - does the findings correlate with clinical outcomes and patient satisfaction. participants of the second phase of the study will be asked for an appointment to have their shoulders examined with ultrasonography and clinical outcomes are measured using the american shoulder and elbow surgeons (ases) score, the disabilities of the arm, shoulder and hand (dash) questionnaire and the constant-murley score (cms).

high numbers of re-tear after rotator cuff surgery have been shown, though not always influencing patient satisfaction. if there is an atraumatic tendon tear, the risk of having a contralateral rotator cuff tendon tear is high. the aim is to study surgically treated rotator cuff injury patients 5 years after repair to evaluate tendon integrity on ultrasonography and answer the question do the findings correlate with functionality and patient satisfaction. it has been shown that people over the age of 66 who have been diagnosed with rotator cuff tendon tear, have up to 50 % chance of having a rotator cuff tendon tear in contralateral shoulder (yamaguchi, et al. 2006). therefore the study will evaluate the function and the integrity of the rotator cuff in both shoulders.

Eligibility criteria:
inclusion criteria: * patients underwent rotator cuff repair by three orthopaedic surgeons at the tartu university hospital sports traumatology centre between 2013 and 2019. * subject gives an informed consent and is willing to come for one outpatient visit. exclusion criteria: * patients who underwent rotator cuff repair for traumatic tears are excluded from clinical assessment (stage ii). * patients who underwent revision surgery are excluded from clinical assessment (stage ii).

Keywords: rotator cuff injury rotator cuff tears sonography shoulder injuries atraumatic tears shoulder pathology shoulder ultrasound
subsidence of short stem tha with dorr type c

Conditions: Hip Osteoarthritis; Short Stem Prosthesis; Total Hip Arthroplasty (THA)

Summary: total hip arthroplasty (tha) is a widely accepted procedure for the treatment of end-stage hip osteoarthritis. neck preserving short stems have gained popularity in recent years, as they aim to preserve proximal femoral bone stock and enable a more physiological load transfer. however, the use of these stems in patients with specific femoral deformities, such as dorr type c femurs, can present unique challenges. dorr type c femurs are characterized by decreased cortical bone thickness and increased medullary canal width, which can impact the fit and stability of the femoral stem component. short stem total hip arthroplasty has emerged as a potential solution for these patients, as it aims to preserve proximal femoral bone stock and improve load transfer to the surrounding bone. this study seeks to investigate the measured subsidence of short stem total hip arthroplasty in patients with dorr type c femur configuration and the clinical outcomes associated with this approach.

in hip arthroplasty, short stems represent a key advancement in the field of bone-preserving surgical techniques. due to the relatively rapid establishment of short stems, the data situation is lagging behind in some areas, resulting in uncertainties in the indication in certain cases. one of these cases is proximal femurs with a dorr type c configuration. this bone characteristic complicates the implantation of stems due to a thin cortical bone and a wide femoral canal and has been shown to lead to an increased complication rate. the aim of this study is to evaluate the clinical and radiological outcome of short stem implantation in dorr type c femur. the study will include all patients who underwent implantation of the "optimys" short stem from mathys between january 1, 2018 and december 31, 2020 at the hospital ordensklinikum linz barmherzige schwestern. in addition, patients must have a type c femur according to dorr. during a follow-up period of at least two years, the harris hip score, the ucla activity-level scale and the singh index are used to evaluate the clinical course. radiological evaluation is carried out using pre- and postoperative x-rays, which together enable an ebra-fca. a statement on the migration behavior of the cementless implanted short stem in dorr type c femur is expected. to date, it has been controversially discussed whether a dorr type c femur provides enough structural support to achieve good primary stability for a cementless implanted short stem with tapered-wedge design. if this were not the case, the excessive migration behavior would lead to subsidence and subsequently to aseptic stem loosening and even complete failure of the prosthesis.

Eligibility criteria:
inclusion criteria: * tha using optimys short stem from 1.1.2018 bis 31.12.2020 in the institution. * typ c femur according to dorr exclusion criteria: * none
lactate clearance after ripc in liver resection

Conditions: Liver Surgery; Remote Ischaemic Preconditioning

Summary: the primary aim of the study is the evaluation of the efficacy of remote ischemic preconditioning (ripc) in terms of increase of the clearance of lactates 4 hours after the end of the hepatic resection. the secondary aims of the study are represented by the evaluation of the patients' postoperative recovery and the restoration of a normal lactate metabolism.

hepatic surgery includes clamping of the hepatic peduncle (pringle maneuver) to control intraoperative bleeding with a consequent reduction of postoperative complications. surgical manipulations and pringle maneuver, especially if prolonged and/or repeated, can cause ischemia-reperfusion damage. the technique of regional ischemic preconditioning was introduced to improve tolerance to ischemia. however, the scientific evidence currently does not support the routine use of regional ischemic preconditioning in hepatic surgery. it has recently been demonstrated that ischemic preconditioning can be effective when performed in the upper limb (ripc). the main advantages of the remote ischaemic preconditiong compared to the regional one are the ease of use, the reduction of surgical time and hepatic ischemia. one of the most relevant epiphenomena of hepatic ischemia during hepatectomy is an increase in lactate levels in the immediate postoperative period that can be associated with an unfavorable outcome and can affect relevant clinical choices such as admission to intensive care. however, no previous studies have investigated the effectiveness of ripc in improving lactate clearance after liver resection. the investigators hypothesized that applying ripc before the start of the hepatic resection and the associated pringle maneuvers could significantly increase lactate clearance 4 hours after the end of liver resection.

Eligibility criteria:
inclusion criteria: * age ≥18 years * elective liver surgey (laparotomic, laparoscopic and robotic-assisted) * signed informed consent exclusion criteria: * age \<18 years * previous liver intervention including surgical and non surgical approach such as liver radiofrequency ablation and radiation therapy * severe cardiopulmunary diseases * refusal to participate

Keywords: lactate clearance postoperative recovery
clinical outcomes of tislelizumab combined with chemotherapy as induction therapy in stage iii (ctnm-iiib/iiic) nsclc

Conditions: NSCLC Stage IIIB, NSCLC Stage IIIC

Summary: this is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in stage iii (ctnm-iiib/iiic) non-small cell lung cancer.patients meeting inclusion and exclusion criteria were enrolled, with treatment modalities and clinical outcomes of stage iii non-small cell lung cancer (nsclc) patients from multiple tertiary hospitals in real-world settings since august 2020 being collected and analyzed.

key inclusion population： stage iiib/iiic nsclc patients confirmed by histological or cytological examination based on the 8th edition of the ajcc staging system.patients were negative for egfr-sensitive mutations or alk/ros1 fusion alterations. no prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered.ecog ps scores of the enrolled patients ranged from 0 to 2. neoadjuvant/induction therapy regimen: tislelizumab combined with platinum-based doublet chemotherapy was administered for 2-4 cycles, followed by surgical resection or other therapeutic interventions (e.g., radiotherapy/chemotherapy). real-world clinical outcomes were collected and analyzed based on patients' subsequent treatment pathways.

Eligibility criteria:
inclusion criteria: stage iiib/iiic nsclc patients confirmed by histological or cytological examination based on the 8th edition of the ajcc staging system. patients were negative for egfr-sensitive mutations or alk/ros1 fusion alterations. no prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered. ecog ps scores of the enrolled patients ranged from 0 to 2. exclusion criteria: patients with other previous malignancies did not require additional treatment. patients with incomplete key baseline and treatment information:including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant. patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown. prior surgery, radiotherapy or systemic therapy for nsclc, including radiofrequency ablation, etc.
phase ii, randomized, placebo-controlled study of ati-7505 in patients with chronic idiopathic constipation

Conditions: Chronic Constipation

Summary: the purpose of this study is to determine whether ati-7505 is effective in the treatment of chronic idiopathic constipation.

this study is designed to evaluate the safety and efficacy of ati 7505 in generally healthy, adult patients who have had symptoms of chronic idiopathic constipation for at least 6 months as defined in the rome iii criteria.

Eligibility criteria:
inclusion criteria: * written informed consent * 18 and 75 years of age * constipation symptom onset at least 6 months ago \& meet rome iii criteria for chronic constipation * negative colonoscopy or air contrast barium enema within the past 2 years if ≥50 years of age or within the past 5 years if \<50 years of age; * are able to refrain from use of medications known to treat constipation or associated symptoms throughout the study exclusion criteria: * transabdominal surgery, unstable coronary artery disease, organic gastrointestinal disease, collagen vascular disease, or any alarm symptoms within the 6 months prior to screening; * taking prohibited medications (including laxatives, herbal remedies) * participating in another drug or medical device study or use of any investigational drug within 30 days before dosing or planning to use prior to study completion; * qtcb \>440 msec, abnormal 12-lead ecg, family history of sudden death at age \<40 years or history of long qt syndrome * alcohol or drug abuse within the 6 months prior to screening; * autonomic dyssynergic defecation
a phase i trial of zd1694 (tomudex), an inhibitor of thymidylate synthase, in pediatric patients with advanced neoplastic disease

Conditions: Neoplasm

Summary: thymidylate synthase (ts), an enzyme which acts by utilizing 5,10-ch(2)fh(4) in the reductive methylation of deoxyuridylate (dump), is required for the de novo synthesis of thymidylate and is a potential chemotherapeutic target. zd1694 is a new quinazolone folate analog that directly inhibits ts. this phase i trial and pharmacokinetic study will describe and define the toxicities, determine the mtd, and describe the plasma pharmacokinetics of zd1694 in pediatric patients with refractory cancer. the starting dose for this trial will be 2.0 mg/m(2) administered as a 15 minute iv infusion every 21 days.

thymidylate synthase (ts), an enzyme which acts by utilizing 5,10-ch(2)fh(4) in the reductive methylation of deoxyuridylate (dump), is required for the de novo synthesis of thymidylate and is a potential chemotherapeutic target. zd1694 is a new quinazolone folate analog that directly inhibits ts. this phase i trial and pharmacokinetic study will describe and define the toxicities, determine the mtd, and describe the plasma pharmacokinetics of zd1694 in pediatric patients with refractory cancer. the starting dose for this trial will be 2.0 mg/m(2) administered as a 15 minute iv infusion every 21 days.

Eligibility criteria:
disease characteristics: histologically proven malignancy considered refractory to standard therapy. objective evidence of progression on prior therapy required. no leukemia. bone marrow involvement by tumor acceptable. marrow biopsy required if there is a history of involvement or peripheral counts are inadequate. prior/concurrent therapy: biologic therapy: recovery from toxic effects of prior immunotherapy required. chemotherapy: no more than 2 prior chemotherapy regimens and recovered. at least 2 weeks since myelosuppressive therapy (6 weeks since nitrosoureas). endocrine therapy: not specified. radiotherapy: no prior central axis irradiation (i.e., skull, spine, ribs, pelvis). recovery from toxic effects of prior radiotherapy required. surgery: not specified. other: no prior bone marrow transplantation. patient characteristics: age: 21 and under. performance status: ecog 0-2. life expectancy: at least 8 weeks. hematopoietic: (unless histologic evidence of bone marrow involvement by tumor). agc at least 1,500/mm3. platelet count at least 100,000/mm3. hemoglobin at least 8.0 g/dl. prior transfusion acceptable. hepatic: bilirubin no greater than 2 times normal. alt no greater than 2 times normal. renal: creatinine less than 1.5 mg/dl or creatinine clearance greater than 60 ml/min/1.73 sqm. cardiovascular: not specified. pulmonary: not specified. other: no significant accumulation of third space fluid. no significant systemic illness (e.g., infection). no pregnant or nursing women. pregnancy test required in fertile women. all patients or their guardians must sign an informed consent.

Keywords: antifolate inhibitor pharmacokinetics thymidylate synthetase toxicity
arterial spin labeling mri for assessing blood perfusion in the human eye repeatability study and clinical application

Conditions: Retinal Diseases

Summary: the mri perfusion imaging using arterial spin labeling (asl)'s non-invasive technique (i.e. without injection of contrast medium) allows, thanks to recent technological improvement of the spatial resolution, measuring several perfusion parameter of the retinal tissue such as the regional blood flow (rbf) or the cerebral blood flow (cbf) expressed in ml/100g/min. reliable application of asl thus requires the precision and specificity of the mri protocol to be tested.


Eligibility criteria:
inclusion criteria: * carrier of target pathologies: tao optic neuropathy, inflammatory optic neuropathy, ischemic optic neuropathy. * no cardiovascular risk factors or other ophthalmological pathology * adhere to the study protocol after reading the patient information document * signe the informed consent form to participate in the study * do not have any contraindications to an mri examination exclusion criteria * usual contraindications to mri (pacemaker, metallic foreign body, cochlear implant,...) * severe claustrophobia
pilot study to evaluate the use of oroscience topical oral wound emulsion in post operative wound healing

Conditions: Oral Surgical Procedures; Pain

Summary: the purpose of this pilot study is to determine if topical oral wound emulsion (towe) assists with dental wound healing and relieves pain from oral wounds.


Eligibility criteria:
inclusion criteria: * planned dental treatment includes intraoral surgery involving full thickness mucoperiosteal flaps with at least one vertical releasing incision exclusion criteria: * complicated medical history * history of poor patient compliance * presence or placement of materials beneath the suture site

Keywords: oral periodontal gingival intraoral mucosal mucoperiosteal surgery, oral
groups for regaining our wellbeing (grow)

Conditions: Posttraumatic Stress Disorder; Depression

Summary: the proposed study is a randomized, controlled trial that will assess whether two group interventions for ptsd - mindfulness-based stress reduction (mbsr) and cognitive processing therapy-cognitive only (cpt-c) result in similar improvements in ptsd symptoms and health-related quality of life (qol). one hundred fifty-two veterans with ptsd will be randomized to mbsr (n = 76) or cpt-c (n = 76). comprehensive assessments will take place post-treatment and 3 months later.

the proposed study is a randomized, controlled non-inferiority trial that will assess whether mindfulness-based stress reduction (mbsr) and cognitive processing therapy-cognitive only (cpt-c) result in equivalent improvement in both ptsd symptoms and health-related quality of life (qol). ptsd symptoms will be measured by the clinician administered ptsd scale - caps and health-related qol will be measured by the sf-36v mental component summary score - mcs. in an exploratory aim, we will also assess whether there is a clinically meaningful response as defined by improvement in both ptsd symptoms and qol (defined as a reliable change of 12 points on the caps and 10 points on the mcs, respectively, according to the reliable change index).7, 8 one hundred fifty-two veterans with ptsd will be randomized to mbsr (n = 76) or cpt-c (n = 76). comprehensive assessments will take place post-treatment and 3 months later. qualitative analysis of brief semi-structured interview data will be used to identify previously unrecognized factors pertaining to participation, adherence and response to treatment, spirituality and religion as treatment moderators, and to identify common themes that may inform treatment retention efforts for both mbsr and cpt-c. in addition, potential moderators of change in ptsd symptoms and qol for mbsr and cpt-c will be identified.

Eligibility criteria:
inclusion criteria: * veterans with current dsm-v diagnosis of ptsd exclusion criteria: * current substance use disorder other than alcohol, * alcohol involvement that poses a safety concern or is associated with inability to follow through on assessments and class attendance as evinced by past month appointment attendance record in cprs, * suicidal or homicidal ideation with intent or plan within the past 3 months, * self harm in the past 3 months, * a psychotic disorder, * uncontrolled bipolar disorder, * chart diagnoses of borderline personality disorder or antisocial personality disorder, * in-patient admission for psychiatric reasons within the past month, * prior participation in mbsr or cpt.

Keywords: mindfulness behavior therapies, cognitive posttraumatic stress disorder group therapy